CN116171153B - 用于调节剪接的组合物 - Google Patents

用于调节剪接的组合物

Info

Publication number
CN116171153B
CN116171153B CN202180062419.8A CN202180062419A CN116171153B CN 116171153 B CN116171153 B CN 116171153B CN 202180062419 A CN202180062419 A CN 202180062419A CN 116171153 B CN116171153 B CN 116171153B
Authority
CN
China
Prior art keywords
compound
formula
methyl
fluoro
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180062419.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN116171153A (zh
Inventor
M·卢奇欧
B·卢卡斯
王天生
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skihawk Therapy
Original Assignee
Skihawk Therapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skihawk Therapy filed Critical Skihawk Therapy
Publication of CN116171153A publication Critical patent/CN116171153A/zh
Application granted granted Critical
Publication of CN116171153B publication Critical patent/CN116171153B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202180062419.8A 2020-08-05 2021-08-04 用于调节剪接的组合物 Active CN116171153B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063061742P 2020-08-05 2020-08-05
US63/061,742 2020-08-05
PCT/US2021/044528 WO2022031838A1 (en) 2020-08-05 2021-08-04 Compositions for modulating splicing

Publications (2)

Publication Number Publication Date
CN116171153A CN116171153A (zh) 2023-05-26
CN116171153B true CN116171153B (zh) 2025-11-21

Family

ID=80117649

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062419.8A Active CN116171153B (zh) 2020-08-05 2021-08-04 用于调节剪接的组合物

Country Status (13)

Country Link
US (1) US20230331718A1 (https=)
EP (1) EP4192454B1 (https=)
JP (1) JP2023538524A (https=)
KR (1) KR20230048106A (https=)
CN (1) CN116171153B (https=)
AR (1) AR123150A1 (https=)
AU (1) AU2021320763A1 (https=)
CA (1) CA3188104A1 (https=)
IL (1) IL300352A (https=)
MX (1) MX2023001558A (https=)
TW (1) TW202216697A (https=)
UY (1) UY39368A (https=)
WO (1) WO2022031838A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020163248A1 (en) 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
EP3920915A4 (en) * 2019-02-05 2022-10-05 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICE
CN114126613A (zh) 2019-02-05 2022-03-01 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
GB202106871D0 (en) * 2021-05-13 2021-06-30 Addex Pharmaceuticals Sa Novel compounds

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114007613A (zh) * 2019-02-05 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2579949T3 (es) 2010-02-05 2016-08-17 Heptares Therapeutics Limited Derivados de 1,2,4-triazin-4-amina
WO2019028440A1 (en) 2017-08-04 2019-02-07 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATING SPLICING
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
CN112272666A (zh) 2018-04-10 2021-01-26 斯基霍克疗法公司 用于治疗癌症的化合物
WO2020163248A1 (en) * 2019-02-04 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
EP3920918A4 (en) * 2019-02-05 2022-11-16 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
WO2022031998A2 (en) 2020-08-05 2022-02-10 Skyhawk Therapeutics, Inc. Process for the preparation of intermediates useful in the preparation of compounds that modulate splicing

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114007613A (zh) * 2019-02-05 2022-02-01 斯基霍克疗法公司 用于调节剪接的方法和组合物

Also Published As

Publication number Publication date
AR123150A1 (es) 2022-11-02
IL300352A (en) 2023-04-01
CN116171153A (zh) 2023-05-26
US20230331718A1 (en) 2023-10-19
WO2022031838A1 (en) 2022-02-10
EP4192454A4 (en) 2024-09-11
EP4192454A1 (en) 2023-06-14
TW202216697A (zh) 2022-05-01
CA3188104A1 (en) 2022-02-10
UY39368A (es) 2022-01-31
JP2023538524A (ja) 2023-09-08
KR20230048106A (ko) 2023-04-10
MX2023001558A (es) 2023-04-26
AU2021320763A1 (en) 2023-03-30
EP4192454B1 (en) 2026-04-22

Similar Documents

Publication Publication Date Title
CN116171153B (zh) 用于调节剪接的组合物
US10941160B2 (en) Bromodomain inhibitors
JP5820921B2 (ja) １，２−二置換複素環式化合物
CN116265462B (zh) 一种具有抗肿瘤活性的杂环化合物及其用途
US10138249B2 (en) Triazolopyridines and triazolopyrazines as LSD1 inhibitors
TWI766882B (zh) 新穎化合物類
US10259816B2 (en) Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
WO2022060951A1 (en) Compositions for modulating splicing
CN116568302A (zh) 杂环取代的稠合γ-咔啉类衍生物、其制备方法、中间体及应用
WO2022060943A1 (en) Compositions for modulating splicing
WO2022116968A1 (zh) 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途
CN116621846B (zh) 双环杂环及三环杂环类化合物及其制备方法和医药用途
CN119874686A (zh) 氘代苯并咪唑衍生物及其制备方法和用途
WO2022060944A1 (en) Compositions for modulating splicing
CN116478147A (zh) 抑制rna解旋酶dhx33活性的氘代化合物、合成方法、药物组合物及用途
EP4514806B1 (en) Compositions useful for modulating splicing
CN118852164A (zh) Parp选择性抑制剂
CN120882700A (zh) miR-124诱导剂及其制备方法和用途
CN118027024A (zh) 吡啶并[1,2-a]嘧啶-4-酮衍生物及其制备方法和用途
CN119403802A (zh) 二并环类mat2a抑制剂及其用途
CN117024441A (zh) 一种mat2a抑制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant